Skip to main content
. 2018 Nov 30;2018(1):177–184. doi: 10.1182/asheducation-2018.1.177

Table 2.

Mechanisms by which posttransplant maintenance therapy can reduce the risk of disease relapse

Antitumor activity against residual leukemic stem and progenitor cells
Postponement of disease relapse thereby buying time for the genesis of a GVL effect
Manipulation of the kinetics of disease relapse permitting postponement of DLI to a later time posttransplant when the risk of severe GVHD is reduced
Pharmacologic manipulation of a GVL response using agents such as azacitidine or sorafenib